<div id="pf1" class="pf w0 h0" data-page-no="1"><div class="pc pc1 w0 h0"><div class="t m0 x0 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">INTERACCI<span class="blank _0"></span>ONES FARMACOLÓGICAS ENTRE WARFARINA Y </div><div class="t m0 x0 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">ENOXAPARINA R<span class="blank _0"></span>EPORTADAS AL <span class="blank _1"> </span>PROGRAMA DISTRITA<span class="blank _0"></span>L DE </div><div class="t m0 x1 h1 y2 ff1 fs0 fc0 sc0 ls0 ws0">FARMACOVIGILANCIA DE BOG<span class="blank _0"></span>OTÁ D.C. 2012- 2016<span class="blank _1"> </span> </div><div class="t m0 x2 h1 y3 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y4 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y5 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y6 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y7 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y8 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y9 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 ya ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 yb ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x3 h1 yc ff1 fs0 fc0 sc0 ls0 ws0">Consu<span class="blank _0"></span>el<span class="blank _1"> </span>o Cald<span class="blank _0"></span>erón Gómez<span class="blank _1"> </span> </div><div class="t m0 x3 h1 yd ff1 fs0 fc0 sc0 ls0 ws0">Ednna Yulieth Castillo<span class="blank _0"></span> Coy<span class="blank _1"> </span> </div><div class="t m0 x2 h1 ye ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 yf ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y10 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y11 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y12 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y13 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y14 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y15 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y16 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x4 h1 y17 ff1 fs0 fc0 sc0 ls0 ws0">UNIV<span class="blank _0"></span>ERSIDAD DE CIENCIAS APLI<span class="blank _1"> </span>CADAS U.D.C.A </div><div class="t m0 x5 h1 y18 ff1 fs0 fc0 sc0 ls0 ws0">FACULTAD<span class="blank _0"></span> DE CIENCIAS DE LA SALUD<span class="blank _1"> </span> </div><div class="t m0 x6 h1 y19 ff1 fs0 fc0 sc0 ls0 ws0">PROGRAMA D<span class="blank _0"></span>E QUÍMICA FARMA<span class="blank _1"> </span>CÉUTICA </div><div class="t m0 x7 h1 y1a ff1 fs0 fc0 sc0 ls0 ws0">BOGOTÁ D.C </div><div class="t m0 x8 h1 y1b ff1 fs0 fc0 sc0 ls0 ws0">2016 </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf2" class="pf w0 h0" data-page-no="2"><div class="pc pc2 w0 h0"><div class="t m0 x0 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">INTERACCI<span class="blank _0"></span>ONES FARMACOLÓGICAS ENTRE WARFARINA Y </div><div class="t m0 x0 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">ENOXAPARINA R<span class="blank _0"></span>EPORTADAS AL <span class="blank _1"> </span>PROGRAMA DISTRITA<span class="blank _0"></span>L DE </div><div class="t m0 x1 h1 y2 ff1 fs0 fc0 sc0 ls0 ws0">FARMACOVIGILANCIA DE BOG<span class="blank _0"></span>OTÁ D.C. 2012- 2016<span class="blank _1"> </span> </div><div class="t m0 x2 h1 y3 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y4 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y5 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x3 h1 y6 ff1 fs0 fc0 sc0 ls0 ws0">Consu<span class="blank _0"></span>el<span class="blank _1"> </span>o Cald<span class="blank _0"></span>erón Gómez<span class="blank _1"> </span> </div><div class="t m0 x3 h1 y7 ff1 fs0 fc0 sc0 ls0 ws0">Ednna Yulieth Castillo<span class="blank _0"></span> Coy<span class="blank _1"> </span> </div><div class="t m0 x2 h1 y8 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y9 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 ya ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x9 h1 yb ff1 fs0 fc0 sc0 ls0 ws0">Trabajo d<span class="blank _0"></span>e gra<span class="blank _1"> </span>do<span class="blank _0"></span> para optar al título de Químico Far<span class="blank _1"> </span>m<span class="blank _0"></span>acéutico <span class="blank _1"> </span> </div><div class="t m0 x2 h1 yc ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 yd ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 ye ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xa h1 yf ff1 fs0 fc0 sc0 ls0 ws0">Director: </div><div class="t m0 xb h1 y10 ff1 fs0 fc0 sc0 ls0 ws0">Juan Sebas<span class="blank _0"></span>tián Sa<span class="blank _1"> </span>bo<span class="blank _0"></span>gal Carmona<span class="blank _1"> </span> </div><div class="t m0 xc h1 y11 ff1 fs0 fc0 sc0 ls0 ws0">Quím<span class="blank _0"></span>ico Far<span class="blank _1"> </span>m<span class="blank _0"></span>acéutico Ms. Toxicología<span class="blank _1"> </span> </div><div class="t m0 x2 h1 y12 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y13 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y14 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y15 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y16 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x4 h1 y17 ff1 fs0 fc0 sc0 ls0 ws0">UNIV<span class="blank _0"></span>ERSIDAD DE CIENCIAS APLI<span class="blank _1"> </span>CADAS U.D.C.A </div><div class="t m0 x5 h1 y18 ff1 fs0 fc0 sc0 ls0 ws0">FACULTAD<span class="blank _0"></span> DE CIENCIAS DE LA SALUD<span class="blank _1"> </span> </div><div class="t m0 x6 h1 y19 ff1 fs0 fc0 sc0 ls0 ws0">PROGRAMA D<span class="blank _0"></span>E QUÍMICA FARMA<span class="blank _1"> </span>CÉUTICA </div><div class="t m0 x7 h1 y1a ff1 fs0 fc0 sc0 ls0 ws0">BOGOTÁ D.C </div><div class="t m0 x8 h1 y1b ff1 fs0 fc0 sc0 ls0 ws0">2016 </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf3" class="pf w0 h0" data-page-no="3"><div class="pc pc3 w0 h0"><img fetchpriority="low" loading="lazy" class="bi xd y1c w1 h2" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg3.png"><div class="t m0 x2 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xe h1 y1d ff1 fs0 fc0 sc0 ls0 ws0">ABREVIATURAS </div><div class="t m0 xd h3 y1e ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y1f ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y20 ff2 fs0 fc0 sc0 ls0 ws0">A<span class="blank _0"></span>nticoagulantes Orale<span class="blank _1"> </span>s (A<span class="blank _0"></span>CO) <span class="blank _1"> </span> </div><div class="t m0 xd h3 y21 ff2 fs0 fc0 sc0 ls0 ws0">A<span class="blank _0"></span>ntitrombi<span class="blank _1"> </span>na III<span class="blank _0"></span> (ATIII) </div><div class="t m0 xd h3 y22 ff2 fs0 fc0 sc0 ls0 ws0">Concentración Máxima Tolerada (CMT)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y23 ff2 fs0 fc0 sc0 ls0 ws0">Concentración Mínima <span class="blank _1"> </span>Eficaz<span class="blank _0"></span> (CME) </div><div class="t m0 xd h3 y24 ff2 fs0 fc0 sc0 ls0 ws0">Enfermedad Cardiovascular (ECV) </div><div class="t m0 xd h3 y25 ff2 fs0 fc0 sc0 ls0 ws0">Error de medicación (EM) </div><div class="t m0 xd h3 y26 ff2 fs0 fc0 sc0 ls0 ws0">Escala de Probabilidad de I<span class="blank _0"></span>nterac<span class="blank _1"> </span>ciones Farmacológ<span class="blank _0"></span>icas (EPIF)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y27 ff2 fs0 fc0 sc0 ls0 ws0">Evento A<span class="blank _0"></span>dverso (EA) </div><div class="t m0 xd h3 y28 ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>actor de Von Willebra<span class="blank _1"> </span>nd (F<span class="blank _0"></span>VW) </div><div class="t m0 xd h3 y29 ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>ármaco Obje<span class="blank _1"> </span>to (FO<span class="blank _0"></span>) </div><div class="t m0 xd h3 y2a ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>ármaco Prec<span class="blank _1"> </span>ipitante (F<span class="blank _0"></span>P) </div><div class="t m0 xd h3 y2b ff2 fs0 fc0 sc0 ls0 ws0">H<span class="blank _0"></span>eparina<span class="blank _1"> </span>s de B<span class="blank _0"></span>ajo Peso Molec<span class="blank _1"> </span>ular (HBPM) </div><div class="t m0 xd h3 y2c ff2 fs0 fc0 sc0 ls0 ws0">H<span class="blank _0"></span>eparina<span class="blank _1"> </span>s no Fraccionadas (H<span class="blank _0"></span>NF) </div><div class="t m0 xd h3 y2d ff2 fs0 fc0 sc0 ls0 ws0">Interacciones F<span class="blank _0"></span>armacológicas (IF) </div><div class="t m0 xd h3 y2e ff2 fs0 fc0 sc0 ls0 ws0">International Normalizated Ratio (IN<span class="blank _0"></span>R) <span class="blank _1"> </span> </div><div class="t m0 xd h3 y2f ff2 fs0 fc0 sc0 ls0 ws0">Problemas Relacionados con los Medicamentos (PRM<span class="blank _0"></span>)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y30 ff2 fs0 fc0 sc0 ls0 ws0">Problemas Relacionados con Medicamentos<span class="blank _0"></span> (PRM)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y31 ff2 fs0 fc0 sc0 ls0 ws0">Proteína Plasmática (PP) </div><div class="t m0 xd h3 y32 ff2 fs0 fc0 sc0 ls0 ws0">Reacción adversa a medicamentos (RA<span class="blank _0"></span>M)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y33 ff2 fs0 fc0 sc0 ls0 ws0">Reacciones Adversas a Medicamentos (R<span class="blank _0"></span>AM) <span class="blank _1"> </span> </div><div class="t m0 xd h3 y34 ff2 fs0 fc0 sc0 ls0 ws0">Resultados Negativos<span class="blank _0"></span> Asociados a la Medicación (RNM)<span class="blank _1"> </span> </div><div class="t m0 xd h3 y35 ff2 fs0 fc0 sc0 ls0 ws0">Sistema Obligatorio de G<span class="blank _0"></span>arantía<span class="blank _1"> </span> de Calida<span class="blank _0"></span>d de la Atención en Salud (SGG<span class="blank _0"></span>C)<span class="blank _2"> </span> </div><div class="t m0 xd h3 y36 ff2 fs0 fc0 sc0 ls0 ws0">Tiempo de Protombina (TP) </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf4" class="pf w0 h0" data-page-no="4"><div class="pc pc4 w0 h0"><img fetchpriority="low" loading="lazy" class="bi xd y37 w2 h4" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg4.png"><div class="t m0 xd h3 y38 ff2 fs0 fc0 sc0 ls0 ws0">Tiempo Parcial de Tromboplastina (TPT) </div><div class="t m0 xd h3 y39 ff2 fs0 fc0 sc0 ls0 ws0">Trombosis Venosa Profunda (TVP) </div><div class="t m0 xd h3 y1e ff2 fs0 fc0 sc0 ls0 ws0">Vía de administración Intravenosa (I<span class="blank _0"></span>V) <span class="blank _1"> </span> </div><div class="t m0 xd h3 y3a ff2 fs0 fc0 sc0 ls0 ws0">Vía de Administración Oral (VO) </div><div class="t m0 xd h3 y20 ff2 fs0 fc0 sc0 ls0 ws0">Vitamina K (VK<span class="blank _0"></span>) <span class="blank _1"> </span> </div><div class="t m0 xd h3 y21 ff2 fs0 fc0 sc0 ls0 ws0">Warfarina (WA<span class="blank _0"></span>R) </div><div class="t m0 x2 h1 y3b ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y3c ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y3d ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y3e ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y3f ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y40 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y41 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y42 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y43 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y44 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y45 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y46 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y47 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y48 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y49 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y4a ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h1 y4b ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h1 y4c ff1 fs0 fc0 sc0 ls0 ws0"> <span class="blank _3"> </span> </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf5" class="pf w0 h0" data-page-no="5"><div class="pc pc5 w0 h0"><img fetchpriority="low" loading="lazy" class="bi xd y4d w3 h5" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg5.png"><div class="t m0 xd h3 y38 ff2 fs0 fc0 sc0 ls1 ws0"> <span class="ff1 ls0 v1">TABLA DE C<span class="blank _0"></span>ONTENIDO<span class="blank _1"> </span> </span></div><div class="t m0 xd h1 y4e ff1 fs0 fc0 sc0 ls0 ws0"> <span class="blank _4"> </span> <span class="blank _5"> </span> <span class="blank _6"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> Pág. </div><div class="t m0 xd h3 y4f ff2 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E <span class="blank _1"> </span>G<span class="blank _0"></span>RÁ<span class="blank _1"> </span>F<span class="blank _0"></span>ICAS<span class="blank _1"> </span><span class="ff3"> <span class="blank _7"></span><span class="ls7 ws1">..........................................................................................................<span class="ls0 ws0"> <span class="blank _8"></span>6<span class="fs1"> </span></span></span></span></div><div class="t m0 xd h3 y50 ff2 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E T<span class="blank _1"> </span>ABLA<span class="blank _0"></span>S<span class="ff3"> <span class="blank _8"></span><span class="ls7 ws1">..............................................................................................................<span class="ls0 ws0"> <span class="blank _8"></span>7<span class="fs1"> </span></span></span></span></div><div class="t m0 xd h3 y51 ff2 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E <span class="blank _1"> </span>F<span class="blank _0"></span>IGURAS<span class="blank _1"> </span><span class="ff3"> <span class="ls7 ws1">............................................................................................................</span> <span class="blank _8"></span>8<span class="fs1"> </span></span></div><div class="t m0 xd h3 y52 ff2 fs0 fc0 sc0 ls0 ws2">IN<span class="blank _0"></span>TRODUCC<span class="blank"> </span>IÓN<span class="ff3 ws0"> <span class="blank _7"></span><span class="ls7 ws1">..................................................................................................................<span class="ls0 ws0"> <span class="blank _8"></span>9<span class="fs1"> </span></span></span></span></div><div class="t m0 xd h3 y7 ff2 fs0 fc0 sc0 ls0 ws3">1.<span class="ff3 fs1 ls2 ws0"> </span>OB<span class="blank _0"></span>JET<span class="blank _1"> </span>IVOS<span class="ff3 ws0"> <span class="blank _8"></span><span class="ls7 ws1">.............................................................................................................<span class="ls0 ws0"> <span class="blank _8"></span><span class="ls8 ws4">12<span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 xf h6 y53 ff2 fs1 fc0 sc0 ls0 ws0">1.2 OBJETIVOS<span class="blank _0"></span> ESPECÍFICOS<span class="blank _1"> </span><span class="ff3"> <span class="blank _8"></span><span class="ls3 ws5">................................................................................................<span class="blank _1"> </span><span class="ls9 ws6">12<span class="ls0 ws0"> </span></span></span></span></div><div class="t m0 xd h3 y54 ff2 fs0 fc0 sc0 ls0 ws3">2.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws0">MARCO TEÓRICO.<span class="ff3"> <span class="ls7 ws1">................................................................................................</span> <span class="blank _9"></span><span class="ls8 ws4">13<span class="fs1 ls0 ws0"> </span></span></span></span></div><div class="t m0 xf h6 y55 ff2 fs1 fc0 sc0 ls0 ws0">2.1 EPIDEMIOL<span class="blank _0"></span>OG<span class="blank _1"> </span>I<span class="blank _0"></span>A DE LAS ENFERMEDADES CARDI<span class="blank _0"></span>OVASCULARES<span class="blank _2"> </span><span class="ff3"> <span class="ls3">.....................<span class="ls9 ws6">13</span></span> </span></div><div class="t m0 x10 h7 y56 ff2 fs2 fc0 sc0 ls0 ws0">2.1.1 <span class="blank _1"> </span>An<span class="blank _0"></span>teceden<span class="blank _0"></span>tes de <span class="blank _1"> </span>las<span class="blank _0"></span> Enfermedades de<span class="blank _1"> </span>l<span class="blank _0"></span> Sistema Ci<span class="blank _0"></span>rcu<span class="blank _1"> </span>latorio en Colombia.<span class="blank _1"> </span><span class="ff3"> <span class="blank _0"></span><span class="ls4 ws7">................................<span class="ls0 ws0">. <span class="blank _a"></span><span class="lsa ws8">13<span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y57 ff2 fs2 fc0 sc0 ls0 ws0">2.1.2 <span class="blank _1"> </span>cl<span class="blank _0"></span>asifica<span class="blank _0"></span>ción internacional de enfermedades CIE<span class="blank _1"> </span>- 10<span class="ff3"> <span class="blank _b"></span><span class="ls4 ws7">..................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">14<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y58 ff2 fs2 fc0 sc0 ls0 ws0">2.1.3 Antecedentes de Even<span class="blank _0"></span>to<span class="blank _1"> </span>s Adv<span class="blank _0"></span>ersos Asociados a <span class="blank _1"> </span>W<span class="blank _0"></span>arfarin<span class="blank _0"></span>a.<span class="blank _2"> </span><span class="ff3 ls5"> <span class="ls4 ws7">.......................................................</span><span class="ls0"> <span class="blank _a"></span><span class="lsa ws8">17<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></div><div class="t m0 xf h6 y59 ff2 fs1 fc0 sc0 ls0 ws9">2.2<span class="ff3 ls6 ws0"> </span><span class="ws0">COAGULACIÓN Y HEMOSTASIA<span class="blank _0"></span>.<span class="blank _1"> </span><span class="ff3"> <span class="blank _7"></span><span class="ls3 ws5">.................................................................................<span class="ls9 ws6">18<span class="ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y5a ff2 fs2 fc0 sc0 ls0 ws0">2.2.1. <span class="blank _1"> </span>Hem<span class="blank _b"></span>o<span class="blank _1"> </span>stas<span class="blank _1"> </span>i<span class="blank _0"></span>a primaria.<span class="ff3"> <span class="blank _8"></span><span class="ls4 ws7">.................................................................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">18<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y5b ff2 fs2 fc0 sc0 ls0 ws0">2.2.2. Hem<span class="blank _0"></span>ost<span class="blank _1"> </span>asi<span class="blank _0"></span>a secundar<span class="blank _1"> </span>ia.<span class="ff3 ls5"> <span class="ls4 ws7">..............................................................................................................</span><span class="ls0"> <span class="blank _a"></span><span class="lsa ws8">19<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></div><div class="t m0 xf h6 y5c ff2 fs1 fc0 sc0 ls0 ws9">2.3<span class="ff3 ls6 ws0"> </span><span class="ws0">TERAPIA ANTI<span class="blank _0"></span>COAGULAN<span class="blank _1"> </span><span class="lsb wsa">TE<span class="blank"> </span></span><span class="ff3"> <span class="blank _7"></span><span class="ls3 ws5">................................<span class="blank _1"> </span>.......................................................<span class="ls9 ws6">22<span class="ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y5d ff2 fs2 fc0 sc0 ls0 ws0">2.3.1. Warfarina Sódi<span class="blank _0"></span>ca.<span class="blank _1"> </span><span class="ff3"> <span class="blank _9"></span><span class="ls4 ws7">.......................................................................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">22<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h8 y5e ff3 fs2 fc0 sc0 ls0 ws0">2.3.2 Moni<span class="blank _0"></span>torización clínica del tratamiento con Warfarina.<span class="blank _1"> </span> <span class="blank _8"></span><span class="ls4 ws7">................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">23<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></div><div class="t m0 x10 h7 y5f ff2 fs2 fc0 sc0 ls0 ws0">2.3.3 <span class="blank _1"> </span>Heparin<span class="blank _b"></span>as de Ba<span class="blank _1"> </span>j<span class="blank _0"></span>o Peso<span class="blank _1"> </span> Molec<span class="blank _0"></span>ular HBPM.<span class="blank _1"> </span><span class="ff3 ls4 ws7">..................................................................................</span><span class="ff3"> <span class="blank _a"></span><span class="lsa ws8">24<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></div><div class="t m0 x10 h7 y60 ff2 fs2 fc0 sc0 ls0 ws0">2.3.4 <span class="blank _1"> </span>M<span class="blank _0"></span>onitori<span class="blank _0"></span>zac<span class="blank _1"> </span>i<span class="blank _0"></span>ó<span class="blank _1"> </span>n clí<span class="blank _0"></span>nica de<span class="blank _1"> </span>l<span class="blank _0"></span> tr<span class="blank _1"> </span>a<span class="blank _0"></span>tamiento <span class="blank _1"> </span>c<span class="blank _0"></span>on HBPM<span class="blank _1"> </span><span class="ff3"> <span class="blank _0"></span><span class="ls4 ws7">......................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">30<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 xf h6 y61 ff2 fs1 fc0 sc0 ls0 ws9">2.4<span class="ff3 ls6 ws0"> </span><span class="wsb">FARMACOVIGILA<span class="blank _0"></span>NC<span class="blank"> </span>IA<span class="ff3 ws0"> <span class="blank _8"></span><span class="ls3 ws5">..................................................................................................<span class="ls9 ws6">31<span class="ls0 ws0"> </span></span></span></span></span></div><div class="t m0 x10 h7 y62 ff2 fs2 fc0 sc0 ls0 ws0">2.4.1 <span class="blank _1"> </span>CONCEP<span class="blank _0"></span>TOS DE FARMAC<span class="blank _0"></span>OVIGILANCIA<span class="blank _1"> </span><span class="ff3"> <span class="blank _7"></span><span class="ls4 ws7">.............................................................................<span class="ls0 ws0"> <span class="blank _a"></span><span class="lsa ws8">33<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></div><div class="t m0 xf h6 y63 ff2 fs1 fc0 sc0 ls0 ws9">2.5<span class="ff3 ls6 ws0"> </span><span class="ws0">ESCALA DE PROBABILI<span class="blank _0"></span>DAD DE INTERACCIONES FARMACOL<span class="blank _0"></span>ÓG<span class="blank _1"> </span>I<span class="blank _0"></span>C<span class="blank _1"> </span>AS<span class="blank _0"></span> (EP<span class="blank _1"> </span>IF) O </span></div><div class="t m0 x11 h6 y64 ff2 fs1 fc0 sc0 ls0 ws0">AL<span class="blank _0"></span>GOR<span class="blank _1"> </span>IT<span class="blank _0"></span>MO DE H<span class="blank _1"> </span>ORN.<span class="ff3"> <span class="blank _7"></span><span class="ls3 ws5">..................................................................................................<span class="ls9 ws6">43<span class="ls0 ws0"> </span></span></span></span></div><div class="t m0 xd h3 y65 ff2 fs0 fc0 sc0 ls0 ws3">3.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws0">MATERIALES<span class="blank _0"></span> Y MÉTODOS<span class="blank _1"> </span><span class="ff3"> <span class="blank _9"></span><span class="ls7 ws1">.................................................................................<span class="ls0 ws0"> <span class="blank _9"></span><span class="ls8 ws4">46<span class="fs1 ls0 ws0"> </span></span></span></span></span></span></div><div class="t m0 xd h3 y66 ff2 fs0 fc0 sc0 ls0 ws3">4.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws0">RESULTA<span class="blank _0"></span>DOS Y D<span class="blank _1"> </span>IS<span class="blank _0"></span>CUSIONES<span class="blank _1"> </span><span class="ff3 ls7 ws1">..........................................................................</span><span class="ff3"> <span class="blank _9"></span><span class="ls8 ws4">48<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></div><div class="t m0 xd h3 y67 ff2 fs0 fc0 sc0 ls0 ws3">5.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws2">CONCL<span class="blank _0"></span>USIONES<span class="blank"> </span><span class="ff3 ws0"> <span class="blank _9"></span><span class="ls7 ws1">................................................................<span class="blank _1"> </span>....................................<span class="ls0 ws0"> <span class="blank _9"></span><span class="ls8 ws4">72<span class="fs1 ls0 ws0"> </span></span></span></span></span></span></div><div class="t m0 xd h3 y68 ff2 fs0 fc0 sc0 ls0 ws3">6.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws2">RECOMENDACI<span class="blank _0"></span>ONES<span class="blank"> </span><span class="ff3 ws0"> <span class="blank _c"></span><span class="ls7 ws1">...........................................................................................<span class="ls0 ws0"> <span class="blank _9"></span><span class="ls8 ws4">74<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></span></div><div class="t m0 xd h3 y69 ff2 fs0 fc0 sc0 ls0 ws3">7.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws0">IMPACTO ESP<span class="blank _0"></span>ERADO<span class="blank _1"> </span><span class="ff3"> <span class="blank _c"></span><span class="ls7 ws1">................................................................<span class="blank _1"> </span>...........................<span class="ls0 ws0"> <span class="blank _9"></span><span class="ls8 ws4">76<span class="fs1 ls0 ws0"> </span></span></span></span></span></span></div><div class="t m0 xd h3 y6a ff2 fs0 fc0 sc0 ls0 ws3">8.<span class="ff3 fs1 ls2 ws0"> </span><span class="ws2">BIBLIOG<span class="blank _0"></span>RA<span class="blank"> </span>FÍA.<span class="ff3 ws0"> <span class="blank _b"></span><span class="ls7 ws1">.....................................................................................................<span class="ls0 ws0"> <span class="blank _9"></span><span class="ls8 ws4">77<span class="blank"> </span><span class="fs1 ls0 ws0"> </span></span></span></span></span></span></div><div class="t m0 xd h3 y6b ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 y6c ff2 fs0 fc0 sc0 ls0 ws0"> </div><a class="l" data-dest-detail="[6,"XYZ",82,721,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:641.690000px;width:445.900000px;height:15.800000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[7,"XYZ",82,721,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:619.880000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[8,"XYZ",82,721,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:598.070000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[9,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:576.260000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[12,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:554.450000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[12,"XYZ",82,517,null]"><div class="d m1" style="border-style:none;position:absolute;left:97.000000px;bottom:533.960000px;width:431.700000px;height:20.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[13,"XYZ",82,664,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:512.150000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[13,"XYZ",82,616,null]"><div class="d m1" style="border-style:none;position:absolute;left:97.000000px;bottom:491.660000px;width:431.700000px;height:20.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[13,"XYZ",82,503,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:478.490000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[14,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:465.320000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[17,"XYZ",82,323,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:452.140000px;width:423.900000px;height:13.180000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[18,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:97.000000px;bottom:431.650000px;width:431.700000px;height:20.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[18,"XYZ",82,473,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:418.480000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[19,"XYZ",82,592,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:405.310000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[22,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:97.000000px;bottom:384.820000px;width:431.700000px;height:20.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[22,"XYZ",82,408,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:371.640000px;width:423.900000px;height:13.180000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[23,"XYZ",82,302,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:358.470000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[24,"XYZ",82,423,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:345.300000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[30,"XYZ",82,128,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:332.120000px;width:423.900000px;height:13.180000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[31,"XYZ",82,410,null]"><div class="d m1" style="border-style:none;position:absolute;left:97.000000px;bottom:311.630000px;width:431.700000px;height:20.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[33,"XYZ",82,568,null]"><div class="d m1" style="border-style:none;position:absolute;left:104.800000px;bottom:298.460000px;width:423.900000px;height:13.170000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[43,"XYZ",82,616,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:278.810000px;width:446.400000px;height:19.650000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[43,"XYZ",82,616,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:264.320000px;width:445.900000px;height:14.490000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[46,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:242.510000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[48,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:220.700000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[72,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:198.890000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[74,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:177.080000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[76,"XYZ",82,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:155.280000px;width:445.900000px;height:21.800000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[77,"XYZ",118,672,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:133.470000px;width:445.900000px;height:21.810000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf6" class="pf w0 h0" data-page-no="6"><div class="pc pc6 w0 h0"><img fetchpriority="low" loading="lazy" class="bi x12 y6d w4 h9" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg6.png"><div class="t m0 x12 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E GRÁFICAS<span class="blank _1"> </span> </div><div class="t m0 xd h1 y1 ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h1 y6e ff1 fs0 fc0 sc0 ls0 ws0"> <span class="ff2"> </span></div><div class="t m0 xd h3 y6f ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 1 Re<span class="blank _1"> </span>porte de interacciones por año <span class="blank _d"> </span>48 </div><div class="t m0 xd h3 y70 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 2 Cla<span class="blank _1"> </span>sificación de evento adverso <span class="blank _e"> </span>49 </div><div class="t m0 xd h3 y71 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 3 Distribuc<span class="blank _1"> </span>ión por edad de pacientes con interacciones<span class="blank _0"></span> Warfarina<span class="blank _2"> </span>- Enoxaparina <span class="blank _f"> </span>50 </div><div class="t m0 xd h3 y72 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 4 Distribuc<span class="blank _1"> </span>ión por género de pacientes con IF<span class="blank _b"></span> ent<span class="blank _1"> </span>re warfarina E<span class="blank _1"> </span>noxaparina <span class="blank _10"> </span>52 </div><div class="t m0 xd h3 y73 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 5 Cla<span class="blank _1"> </span>sificación RNM <span class="blank _11"> </span>53 </div><div class="t m0 xd h3 y74 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 6 Serie<span class="blank _1"> </span>dad Interacciones Warfarin<span class="blank _0"></span>a<span class="blank _1"> </span>-Enoxaparina <span class="blank _12"> </span>54 </div><div class="t m0 xd h3 y75 ff2 fs0 fc0 sc0 ls0 ws0">G<span class="blank _0"></span>rafico 7 Ca<span class="blank _1"> </span>usalidad Alg<span class="blank _0"></span>oritmo de Horn<span class="blank _1"> </span> <span class="blank _13"> </span>70 </div><div class="t m0 xd h3 y76 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y77 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y78 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y79 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7a ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7b ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7c ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7d ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7e ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y7f ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y80 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y81 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y82 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y83 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y84 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y85 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y86 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y87 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y88 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y89 ff2 fs0 fc0 sc0 ls0 ws0"> </div><a class="l" data-dest-detail="[48,"XYZ",82,485,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:642.600000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[49,"XYZ",82,370,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:627.710000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[50,"XYZ",82,624,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:612.820000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[52,"XYZ",82,670,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:597.930000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[53,"XYZ",82,632,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:583.040000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[54,"XYZ",82,670,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:568.150000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[70,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:553.250000px;width:445.900000px;height:14.900000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf7" class="pf w0 h0" data-page-no="7"><div class="pc pc7 w0 h0"><img fetchpriority="low" loading="lazy" class="bi x13 y6d w5 h9" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg7.png"><div class="t m0 x13 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E TABLAS<span class="blank _1"> </span> </div><div class="t m0 x2 h8 y8a ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h8 y8b ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 y8c ff2 fs0 fc0 sc0 ls0 ws0">Tabla 1. Nomenclatura internacional de los<span class="blank _0"></span> factores de coagulación y<span class="blank _0"></span> caract<span class="blank _1"> </span>erísti<span class="blank _0"></span>cas </div><div class="t m0 xd h3 y8d ff2 fs0 fc0 sc0 ls0 ws0">generales. <span class="blank _9"></span>................................<span class="blank _1"> </span>.............................................................................................. <span class="blank _9"></span>21 </div><div class="t m0 xd h3 y8e ff2 fs0 fc0 sc0 ls0 ws0">Tabla 2. Clasificación de los factores de c<span class="blank _0"></span>oagulación de acuerdo a sus característica<span class="blank _0"></span>s.<span class="blank _1"> </span> <span class="blank _7"></span>...... <span class="blank _9"></span>21 </div><div class="t m0 xd h3 y8f ff2 fs0 fc0 sc0 ls0 ws0">Tabla 3. Diferencias entre las HB<span class="blank _0"></span>PM.<span class="blank _1"> </span> <span class="blank _7"></span>.................................................................................. <span class="blank _9"></span>30 </div><div class="t m0 xd h3 y90 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 4. <span class="blank _1"> </span> Categorías de <span class="blank _0"></span>Evitabilidad del evento adv<span class="blank _0"></span>erso<span class="blank _1"> </span> <span class="blank _14"></span>...................................................... <span class="blank _9"></span>34 </div><div class="t m0 xd h3 y91 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 5. L<span class="blank _0"></span>istado de PRM<span class="blank _1"> </span> <span class="blank _7"></span>...................................................................................................... <span class="blank _9"></span>37 </div><div class="t m0 xd h3 y92 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 6. Escala de probabilidad de interacciones farmaco<span class="blank _0"></span>lógicas de H<span class="blank _0"></span>orn.<span class="blank _2"> </span> <span class="blank _b"></span>........................ <span class="blank _9"></span>44 </div><div class="t m0 xd h3 y93 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 7. Descripción de Variables <span class="blank _14"></span>........................................................................................ <span class="blank _9"></span>46 </div><div class="t m0 xd h3 y94 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 8. Reporte seriedad grav<span class="blank _0"></span>e Muerte<span class="blank _1"> </span> <span class="blank _14"></span>............................................................................... <span class="blank _9"></span>54 </div><div class="t m0 xd h3 y95 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 9. Uso de antiagreg<span class="blank _0"></span>antes plaqueta<span class="blank _1"> </span>ri<span class="blank _0"></span>os como parte de tratamiento en pacien<span class="blank _0"></span>tes con <span class="blank _2"> </span> </div><div class="t m0 xd h3 y96 ff2 fs0 fc0 sc0 ls0 ws0">A<span class="blank _0"></span>CV<span class="blank _1"> </span> <span class="blank _14"></span>................................<span class="blank _1"> </span>...................................................................................................... <span class="blank _9"></span>55 </div><div class="t m0 xd h3 y97 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 10. Recomendación uso de antia<span class="blank _1"> </span>gre<span class="blank _0"></span>g<span class="blank _0"></span>ante dual<span class="blank _1"> </span> en ACV <span class="blank _b"></span>............................................ <span class="blank _9"></span>56 </div><div class="t m0 xd h3 y98 ff2 fs0 fc0 sc0 ls0 ws0">Tabla 11. Recomendaciones uso de medicamentos que manej<span class="blank _0"></span>an el flujo vascular en<span class="blank _1"> </span> </div><div class="t m0 xd h3 y99 ff2 fs0 fc0 sc0 ls0 ws0">A<span class="blank _0"></span>CV<span class="blank _1"> </span> <span class="blank _14"></span>................................<span class="blank _1"> </span>...................................................................................................... <span class="blank _9"></span>56 </div><div class="t m0 xd h3 y9a ff2 fs0 fc0 sc0 ls0 ws0">Tabla 12. Descriptores Whoart <span class="blank _7"></span>............................................................................................. <span class="blank _9"></span>58 </div><div class="t m0 xd h3 y9b ff2 fs0 fc0 sc0 ls0 ws0">Tabla 13. Clasificación de whoart-subwhoart <span class="blank _8"></span>...................................................................... <span class="blank _9"></span>59 </div><div class="t m0 xd h3 y5b ff2 fs0 fc0 sc0 ls0 ws0">Tabla 14. Indicaciones clínicas y<span class="blank _b"></span> <span class="blank _1"> </span>valor de INR rec<span class="blank _1"> </span>omendado<span class="blank _1"> </span> <span class="blank _8"></span>........................................... <span class="blank _9"></span>60 </div><div class="t m0 xd h3 y9c ff2 fs0 fc0 sc0 ls0 ws0">Tabla 15. Factores de Riesgo de Sang<span class="blank _0"></span>rado<span class="blank _1"> </span> <span class="blank _c"></span>........................................................................... <span class="blank _9"></span>61 </div><div class="t m0 xd h3 y9d ff2 fs0 fc0 sc0 ls0 ws0">Tabla 16. Fármacos que aumentan el riesgo de hemorragia................................................. <span class="blank _9"></span>64 </div><div class="t m0 xd h3 y9e ff2 fs0 fc0 sc0 ls0 ws0">Tabla 17. Interacciones medicamentosas con w<span class="blank _0"></span>arfarina<span class="blank _1"> </span> <span class="blank _a"></span>...................................................... <span class="blank _9"></span>67 </div><div class="t m0 xd h3 y9f ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya0 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya1 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya2 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya3 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya4 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya5 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya6 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya7 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya8 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ya9 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 yaa ff2 fs0 fc0 sc0 ls0 ws0"> </div><a class="l" data-dest-detail="[21,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:643.460000px;width:446.400000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[21,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:628.560000px;width:445.900000px;height:14.900000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[21,"XYZ",82,292,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:613.670000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[30,"XYZ",82,521,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:598.780000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[34,"XYZ",82,608,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:583.890000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[37,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:569.000000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[44,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:554.110000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[46,"XYZ",82,427,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:539.220000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[54,"XYZ",82,354,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:524.330000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[55,"XYZ",82,465,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:509.430000px;width:446.400000px;height:14.900000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[55,"XYZ",82,465,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:494.540000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[56,"XYZ",82,600,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:479.650000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[56,"XYZ",82,325,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:464.760000px;width:446.400000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[56,"XYZ",82,325,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:449.870000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[58,"XYZ",82,513,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:434.980000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[59,"XYZ",82,632,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:420.090000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[60,"XYZ",82,576,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:405.190000px;width:445.900000px;height:14.900000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[61,"XYZ",82,551,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:390.300000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[64,"XYZ",82,386,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:375.410000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[67,"XYZ",82,402,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:360.520000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf8" class="pf w0 h0" data-page-no="8"><div class="pc pc8 w0 h0"><img fetchpriority="low" loading="lazy" class="bi xd yab w6 ha" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg8.png"><div class="t m0 x14 h1 y0 ff1 fs0 fc0 sc0 ls0 ws0">LISTA D<span class="blank _0"></span>E FIGURAS </div><div class="t m0 xd h8 y8a ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h1 yac ff1 fs0 fc0 sc0 ls0 ws0"> <span class="ff2">Pág. </span></div><div class="t m0 xd h3 yad ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>i<span class="blank _1"> </span>gura N° 1. Cas<span class="blank _0"></span>cada de<span class="blank _1"> </span> coagulación <span class="blank _7"></span>................................................................................... <span class="blank _9"></span>20 </div><div class="t m0 xd h3 yae ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>i<span class="blank _1"> </span>gura N° 2. M<span class="blank _0"></span>ecanismo de a<span class="blank _1"> </span>cción Warfarina <span class="blank _8"></span>.................................................................... <span class="blank _9"></span>23 </div><div class="t m0 xd h3 yaf ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>i<span class="blank _1"> </span>gura N° 3. A<span class="blank _0"></span>dición <span class="blank _1"> </span>y<span class="blank _0"></span> Potencia<span class="blank _1"> </span>ción. <span class="blank _14"></span>................................................................................... <span class="blank _9"></span>41 </div><div class="t m0 xd h3 yb0 ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>i<span class="blank _1"> </span>gura N° 4. A<span class="blank _0"></span>nta<span class="blank _1"> </span>gonismo competitivo. <span class="blank _14"></span>............................................................................... <span class="blank _9"></span>42 </div><div class="t m0 xd h3 yb1 ff2 fs0 fc0 sc0 ls0 ws0">F<span class="blank _0"></span>i<span class="blank _1"> </span>gura N° 5. A<span class="blank _0"></span>lgoritmo de m<span class="blank _1"> </span>anejo de anticoag<span class="blank _0"></span>ulación con Warfarina<span class="blank _1"> </span> <span class="blank _9"></span>................................ <span class="blank _9"></span>62 </div><div class="t m0 xd h3 yb2 ff2 fs0 fc0 sc0 ls0 ws0"> <span class="blank _4"> </span> <span class="blank _5"> </span> <span class="blank _6"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> <span class="blank _4"> </span> </div><div class="t m0 xd h3 yb3 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 yb4 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yb5 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yb6 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yb7 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yb8 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yb9 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yba ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 ybb ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 ybc ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 ybd ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 ybe ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 ybf ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yc0 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yc1 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yc2 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h3 yc3 ff2 fs0 fc0 sc0 ls0 ws0"> </div><a class="l" data-dest-detail="[20,"XYZ",82,584,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:643.030000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[23,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:628.140000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[41,"XYZ",82,463,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:613.250000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[42,"XYZ",82,527,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:598.360000px;width:445.900000px;height:14.890000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" data-dest-detail="[62,"XYZ",82,696,null]"><div class="d m1" style="border-style:none;position:absolute;left:82.800000px;bottom:583.460000px;width:445.900000px;height:14.900000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pf9" class="pf w0 h0" data-page-no="9"><div class="pc pc9 w0 h0"><img fetchpriority="low" loading="lazy" class="bi x15 yc4 w7 hb" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bg9.png"><div class="t m0 x16 h8 yc5 ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 x17 hc yc6 ff4 fs1 fc0 sc0 ls0 ws0">Vicerrectoría de Investigaciones U<span class="blank _1"> </span>.D.C.A<span class="blank _0"></span> | Formato de Presentación ante proyecto de grado </div><div class="t m0 x18 hc yc7 ff4 fs1 fc0 sc0 ls0 ws0">Página 9 </div><div class="t m0 xd h8 yc8 ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 yc9 ff2 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xe h1 yca ff1 fs0 fc0 sc0 ls0 ws0">INTRODUCCI<span class="blank _0"></span>ÓN </div><div class="t m0 xd h1 ycb ff1 fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 ycc ff2 fs0 fc0 sc0 ls0 ws0">L<span class="blank _0"></span>as <span class="blank _2"> </span>inte<span class="blank _1"> </span>racciones <span class="blank _2"> </span>farmacológicas <span class="blank _2"> </span>IF, <span class="blank _2"> </span>son <span class="blank _15"> </span>modificaciones <span class="blank _2"> </span>medibles <span class="blank _2"> </span>en <span class="blank _2"> </span>magnitud <span class="blank _2"> </span>o <span class="blank _2"> </span>duración </div><div class="t m0 xd h3 ycd ff2 fs0 fc0 sc0 ls0 ws0">de la acción farmaco<span class="blank _0"></span>lógica de un med<span class="blank _0"></span>icamento,<span class="lsf"> <span class="blank _1"> </span></span>cuando el ef<span class="blank _0"></span>ecto de este se<span class="blank _0"></span> ve modif<span class="blank _0"></span>icado o </div><div class="t m0 xd h3 yce ff2 fs0 fc0 sc0 lsc wsc">alter<span class="blank _0"></span><span class="ls0 ws0">ado <span class="blank _f"> </span>por <span class="blank _f"> </span>otro <span class="blank _f"> </span>fármaco <span class="blank _f"> </span>que <span class="blank _f"> </span>ha <span class="blank _f"> </span>sido <span class="blank _16"> </span>administrado <span class="blank _f"> </span>prev<span class="blank _0"></span>ia <span class="blank _f"> </span>o <span class="blank _17"> </span> <span class="blank _f"> </span>concomitantement<span class="blank _0"></span>e. <span class="blank _f"> </span>Cabe </span></div><div class="t m0 xd h3 ycf ff2 fs0 fc0 sc0 ls0 ws0">señalar <span class="blank _18"> </span>que <span class="blank _15"> </span>el <span class="blank _15"> </span>e<span class="blank _1"> </span>quilibrio <span class="blank _15"> </span>riesgo <span class="blank _15"> </span>be<span class="blank _1"> </span>neficio <span class="blank _15"> </span>de <span class="blank _18"> </span>un <span class="blank _15"> </span>me<span class="blank _1"> </span>dicamento <span class="blank _15"> </span>se <span class="blank _18"> </span>puede <span class="blank _15"> </span>ver <span class="blank _15"> </span>afec<span class="blank _1"> </span>tado <span class="blank _18"> </span>si <span class="blank _18"> </span> <span class="blank _15"> </span>se </div><div class="t m0 xd h3 yd0 ff2 fs0 fc0 sc0 ls0 ws0">genera <span class="blank _16"> </span>una <span class="blank _16"> </span>gran <span class="blank _f"> </span>incidenci<span class="blank _0"></span>a <span class="blank _16"> </span>de <span class="blank _16"> </span>eventos <span class="blank _16"> </span>adversos<span class="blank _0"></span> <span class="blank _16"> </span>o <span class="blank _16"> </span>reduc<span class="blank _1"> </span>ción <span class="blank _16"> </span>de <span class="blank _16"> </span>la <span class="blank _16"> </span>eficacia<span class="blank _1"> </span> <span class="blank _f"> </span>asoci<span class="blank _0"></span>ada <span class="blank _16"> </span>a <span class="blank _16"> </span>la </div><div class="t m0 xd h3 yd1 ff2 fs0 fc0 sc0 ls0 ws0">interacción<span class="blank _1"> </span> fárm<span class="blank _0"></span>aco <span class="ff5 ws3">\u2013</span> fármaco<span class="blank _1"> </span> <span class="lsd wsd">(1)</span> </div><div class="t m0 xd h3 yd2 ff2 fs0 fc0 sc0 ls0 ws0">L<span class="blank _0"></span>a <span class="blank _18"> </span>t<span class="blank _1"> </span>erapia <span class="blank _16"> </span>anticoagulante <span class="blank _16"> </span>s<span class="blank _0"></span>e <span class="blank _16"> </span>ref<span class="blank _0"></span>iere <span class="blank _18"> </span>al <span class="blank _16"> </span>us<span class="blank _0"></span>o <span class="blank _18"> </span>de <span class="blank _16"> </span>diferentes <span class="blank _18"> </span>agentes <span class="blank _16"> </span>pa<span class="blank _0"></span>ra <span class="blank _19"> </span>controlar <span class="blank _19"> </span> <span class="blank _18"> </span>de <span class="blank _19"> </span>forma </div><div class="t m0 xd h3 y96 ff2 fs0 fc0 sc0 ls0 ws0">directa <span class="blank _16"> </span>o <span class="blank _16"> </span>indirecta <span class="blank _16"> </span>los <span class="blank _19"> </span>fa<span class="blank _1"> </span>ctores <span class="blank _16"> </span>de <span class="blank _19"> </span>c<span class="blank _1"> </span>oagulación, <span class="blank _19"> </span>e<span class="blank _1"> </span>vitando <span class="blank _19"> </span>de <span class="blank _16"> </span>esta <span class="blank _f"> </span>m<span class="blank _1"> </span>anera <span class="blank _19"> </span>l<span class="blank _1"> </span>a <span class="blank _19"> </span>form<span class="blank _1"> </span>ación <span class="blank _19"> </span>de </div><div class="t m0 xd h3 yd3 ff2 fs0 fc0 sc0 ls0 ws0">trombos. <span class="blank _15"> </span>L<span class="blank _0"></span>os <span class="blank _1"> </span>a<span class="blank _1"> </span>nticoagulantes <span class="blank _2"> </span>se <span class="blank _2"> </span>prescri<span class="blank _1"> </span>be<span class="blank _0"></span>n <span class="blank _1"> </span>c<span class="blank _1"> </span>onstantemente <span class="blank _2"> </span>para <span class="blank _2"> </span>el <span class="blank _2"> </span>tratamiento <span class="blank _2"> </span>y<span class="blank _0"></span> <span class="blank _2"> </span>profil<span class="blank _1"> </span>axis </div><div class="t m0 xd h3 yd4 ff2 fs0 fc0 sc0 lsc wsc">en<span class="ls0 ws0"> <span class="blank _18"> </span>pacientes <span class="blank _18"> </span>con <span class="blank _18"> </span>una <span class="blank _18"> </span>varied<span class="blank _0"></span>ad <span class="blank _18"> </span>de <span class="blank _18"> </span>enfermedades <span class="blank _18"> </span>cardiov<span class="blank _0"></span>asculares <span class="blank _18"> </span>como: <span class="blank _19"> </span>trombosis <span class="blank _18"> </span>venosa </span></div><div class="t m0 xd h3 yd5 ff2 fs0 fc0 sc0 ls0 ws0">profunda, <span class="blank _f"> </span>tromboem<span class="blank _1"> </span>bolismo <span class="blank _16"> </span>pulmonar, <span class="blank _17"> </span>pacie<span class="blank _1"> </span>ntes <span class="blank _16"> </span>con <span class="blank _17"> </span>v<span class="blank _0"></span>álvulas <span class="blank _16"> </span>m<span class="blank _1"> </span>ecánicas <span class="blank _f"> </span>en <span class="blank _f"> </span>el <span class="blank _f"> </span>c<span class="blank _1"> </span>orazón,<span class="blank _0"></span> </div><div class="t m0 xd h3 yd6 ff2 fs0 fc0 sc0 ls0 ws0">fibrilación auricular, entre ot<span class="blank _1"> </span>ros <span class="lsd wsd">(2)</span> <span class="lsd wsd">(3)</span>. <span class="blank _0"></span> </div><div class="t m0 xd h3 yd7 ff2 fs0 fc0 sc0 ls0 ws0">Por más de 60 años la Warfar<span class="blank _0"></span>ina es el anticoagulante <span class="blank _1"> </span>de uso oral<span class="blank _0"></span> <span class="lse wse">más</span> utilizado <span class="blank _0"></span>en el mundo,<span class="blank _0"></span> </div><div class="t m0 xd h3 yd8 ff2 fs0 fc0 sc0 ls0 ws0">debido <span class="blank _15"> </span>a <span class="blank _15"> </span>su <span class="blank _15"> </span>buena <span class="blank _15"> </span>absorción<span class="blank _1"> </span> <span class="blank _15"> </span>y<span class="blank _0"></span> <span class="blank _2"> </span>ba<span class="blank _1"> </span>jo <span class="blank _2"> </span>c<span class="blank _1"> </span>osto. <span class="blank _15"> </span>Fue <span class="blank _2"> </span>de<span class="blank _1"> </span>scubierta <span class="blank _15"> </span>por <span class="blank _15"> </span>Karl <span class="blank _2"> </span>Paul <span class="blank _18"> </span>L<span class="blank _0"></span>ink<span class="blank _1"> </span>, <span class="blank _2"> </span>e<span class="blank _1"> </span>n <span class="blank _15"> </span>1941 <span class="blank _15"> </span><span class="lsc">al </span></div><div class="t m0 xd h3 yd9 ff2 fs0 fc0 sc0 ls0 ws0">aislar el di<span class="blank _0"></span>cumarol de <span class="blank _0"></span>la cumarin<span class="blank _0"></span>a, una m<span class="blank _0"></span>olécula deriv<span class="blank _0"></span>ada de una <span class="blank _0"></span>planta <span class="blank _0"></span>llamada "<span class="blank _b"></span>hierba<span class="blank _1"> </span> del<span class="blank _0"></span> </div><div class="t m0 xd h3 yda ff2 fs0 fc0 sc0 ls0 ws0">bisonte" <span class="blank _b"></span>l<span class="blank _1"> </span>a cual género <span class="blank _0"></span>en los <span class="blank _0"></span>años <span class="blank _0"></span>20 un <span class="blank _b"></span>b<span class="blank _1"> </span>rote de enfermedad h<span class="blank _0"></span>emorrágica <span class="blank _0"></span>en <span class="blank _0"></span>el g<span class="blank _0"></span>anado<span class="blank _2"> </span> <span class="lsd wsd">(4)</span>.<span class="blank _0"></span> </div><div class="t m0 xd h3 ydb ff2 fs0 fc0 sc0 ls0 ws0">L<span class="blank _0"></span>a <span class="blank _2"> </span>Warfari<span class="blank _1"> </span>na <span class="blank _2"> </span>es <span class="blank _2"> </span>un <span class="blank _2"> </span>i<span class="blank _1"> </span>nhibidor <span class="blank _2"> </span>de <span class="blank _1"> </span>l<span class="blank _1"> </span>a <span class="blank _2"> </span>vitami<span class="blank _0"></span>na <span class="blank _2"> </span>K, <span class="blank _2"> </span>que <span class="blank _2"> </span>afe<span class="blank _1"> </span>cta <span class="blank _15"> </span>la <span class="blank _1"> </span>sínt<span class="blank _1"> </span>esis <span class="blank _1"> </span>de<span class="blank _1"> </span> <span class="blank _1"> </span>la <span class="blank _2"> </span>e<span class="blank _1"> </span>nzima e<span class="blank _1"> </span>póxido </div><div class="t m0 xd h3 ydc ff2 fs0 fc0 sc0 ls0 ws0">reductasa<span class="blank _1"> </span>, <span class="blank _0"></span>bloqu<span class="blank _0"></span>eando <span class="blank _0"></span>también <span class="blank _0"></span>los <span class="blank _b"></span>fa<span class="blank _1"> </span>ctores<span class="blank _0"></span> <span class="blank _b"></span>de<span class="blank _1"> </span> <span class="blank _0"></span>coagulació<span class="blank _1"> </span>n dependientes<span class="blank _0"></span> <span class="blank _0"></span>de <span class="blank _b"></span>l<span class="blank _1"> </span>a <span class="blank _0"></span>v<span class="blank _0"></span>itamina <span class="blank _0"></span>K<span class="blank _0"></span>;<span class="blank _1"> </span> e<span class="lse">l </span></div><div class="t m0 xd h3 ydd ff2 fs0 fc0 sc0 ls0 ws0">mecanismo <span class="blank _b"></span>de <span class="blank _b"></span>l<span class="blank _1"> </span>a <span class="blank _b"></span>acción <span class="blank _b"></span>de<span class="blank _1"> </span> <span class="blank _b"></span>la W<span class="blank _0"></span>arfarina<span class="blank _1"> </span> <span class="blank _b"></span>justifica <span class="blank _b"></span>su <span class="blank _b"></span>ret<span class="blank _1"> </span>raso <span class="blank _b"></span>en <span class="blank _b"></span>la <span class="blank _0"></span>aparición <span class="blank _b"></span>y <span class="blank _a"></span>la<span class="blank _1"> </span> <span class="blank _b"></span>compensación </div><div class="t m0 xd h3 yde ff2 fs0 fc0 sc0 ls0 ws0">de <span class="blank _a"></span>la<span class="blank _1"> </span> <span class="blank _a"></span>acción;<span class="blank _1"> </span> y<span class="blank _0"></span>a <span class="blank _a"></span>que <span class="blank _b"></span>los <span class="blank _a"></span>fac<span class="blank _1"> </span>tores <span class="blank _a"></span>de <span class="blank _b"></span>coagulación <span class="blank _0"></span>desarrollados <span class="blank _a"></span>antes <span class="blank _b"></span>de <span class="blank _a"></span>l<span class="blank _1"> </span>a <span class="blank _a"></span>ingesta <span class="blank _a"></span>de<span class="blank _1"> </span> <span class="blank _b"></span>Warfarina </div><div class="t m0 xd h3 ydf ff2 fs0 fc0 sc0 ls0 ws0">continúan<span class="blank _1"> </span> funcionando hasta ser depurad<span class="blank _0"></span>os <span class="lsd wsd">(3)</span> <span class="lsd wsd">(5)</span>. </div><div class="t m0 xd h3 ye0 ff2 fs0 fc0 sc0 ls0 ws0">Así mismo las H<span class="blank _b"></span>e<span class="blank _1"> </span>parinas de bajo peso mo<span class="blank _0"></span>lecular (H<span class="blank _0"></span>BPM) fueron introducidas en <span class="blank _0"></span>la <span class="blank _0"></span>práctica </div><div class="t m0 xd h3 ye1 ff2 fs0 fc0 sc0 ls0 ws0">clínica <span class="blank _15"> </span>a <span class="blank _18"> </span>finales<span class="blank _0"></span> <span class="blank _15"> </span>de <span class="blank _15"> </span>1980. <span class="blank _15"> </span> <span class="blank _15"> </span>Poseen <span class="blank _18"> </span>mej<span class="blank _1"> </span>or <span class="blank _2"> </span>absorción <span class="blank _18"> </span>por <span class="blank _2"> </span>vía <span class="blank _15"> </span>subcutánea<span class="blank _1"> </span>, <span class="blank _15"> </span>escasa <span class="blank _15"> </span>variabilidad </div><div class="t m0 xd h3 ye2 ff2 fs0 fc0 sc0 ls0 ws0">individual en<span class="blank _0"></span> tra<span class="blank _0"></span>tamientos, <span class="blank _0"></span>may<span class="blank _0"></span>or <span class="blank _0"></span>unión específica <span class="blank _b"></span>a<span class="blank _1"> </span> pro<span class="blank _0"></span>teínas <span class="blank _0"></span>del <span class="blank _0"></span>plasma <span class="blank _0"></span>A<span class="blank _0"></span>T<span class="blank _2"> </span>III, <span class="blank _0"></span>asegurando </div><div class="t m0 xd h3 ye3 ff2 fs0 fc0 sc0 ls0 ws0">una <span class="blank _17"> </span>mej<span class="blank _1"> </span>or <span class="blank _17"> </span>relación <span class="blank _17"> </span> <span class="blank _17"> </span>dosis-respuesta, <span class="blank _17"> </span>m<span class="blank _1"> </span>enor <span class="blank _17"> </span> <span class="blank _17"> </span>síndrome <span class="blank _17"> </span>de <span class="blank _1a"> </span>trombocitopenia <span class="blank _17"> </span>/trombosis <span class="blank _17"> </span>y </div><div class="t m0 xd h3 ye4 ff2 fs0 fc0 sc0 ls0 ws0">necrosis <span class="blank _18"> </span>cutánea<span class="blank _1"> </span> <span class="blank _18"> </span>(2) <span class="blank _15"> </span><span class="lsd wsd">(6)</span>. <span class="blank _19"> </span>L<span class="blank _0"></span>a <span class="blank _18"> </span>enoxapa<span class="blank _1"> </span>rina <span class="blank _15"> </span>es <span class="blank _18"> </span>una <span class="blank _18"> </span>hepa<span class="blank _1"> </span>rina <span class="blank _18"> </span>de <span class="blank _15"> </span>baj<span class="blank _1"> </span>o <span class="blank _15"> </span>peso <span class="blank _18"> </span>molecular <span class="blank _15"> </span>c<span class="blank _1"> </span>on <span class="blank _18"> </span>una </div><div class="t m0 xd h3 ye5 ff2 fs0 fc0 sc0 ls0 ws0">elevada <span class="blank _2"> </span>actividad <span class="blank _1"> </span>anti<span class="blank _1"> </span>-Xa <span class="blank _1"> </span>(100 <span class="blank _2"> </span>U.I. <span class="blank _2"> </span>/ml) <span class="blank _15"> </span>y <span class="blank _1"> </span>una <span class="blank _2"> </span>dé<span class="blank _1"> </span>bil <span class="blank _1"> </span>actividad <span class="blank _1"> </span>a<span class="blank _1"> </span>nti-IIa <span class="blank _1"> </span>o <span class="blank _2"> </span>a<span class="blank _1"> </span>ntitrombínica <span class="blank _2"> </span>(28<span class="blank _0"></span> </div><div class="t m0 xd h3 ye6 ff2 fs0 fc0 sc0 ls0 ws0">U.I<span class="blank _0"></span>./ml). <span class="blank _19"> </span>E<span class="blank _1"> </span>stas <span class="blank _18"> </span>a<span class="blank _1"> </span>ctividades <span class="blank _19"> </span>anticoagulantes <span class="blank _18"> </span>están <span class="blank _19"> </span>me<span class="blank _1"> </span>diadas <span class="blank _18"> </span>a <span class="blank _19"> </span>tra<span class="blank _1"> </span>vé<span class="blank _1"> </span>s <span class="blank _19"> </span>de <span class="blank _19"> </span>la <span class="blank _19"> </span>anti<span class="blank _1"> </span>trom<span class="blank _0"></span>bina <span class="blank _19"> </span>III </div><div class="t m0 xd h3 ye7 ff2 fs0 fc0 sc0 ls0 ws0">(A<span class="blank _0"></span>T<span class="blank _1"> </span>III) teniendo en humanos actividad an<span class="blank _0"></span>titrombótica <span class="blank _1"> </span><span class="lsd wsd">(7)</span>. </div><div class="t m0 xd h3 ye8 ff2 fs0 fc0 sc0 ls0 ws0">El <span class="blank _1"> </span>pri<span class="blank _1"> </span>ncipal <span class="blank _1"> </span>evento <span class="blank _1"> </span>adverso <span class="blank _1"> </span>asocia<span class="blank _1"> </span>do <span class="blank _1"> </span>a <span class="blank _1"> </span>la <span class="blank _1"> </span>terapia <span class="blank _2"> </span>anticoagulante <span class="blank _1"> </span>es <span class="blank _1"> </span>el <span class="blank _2"> </span>riesg<span class="blank _0"></span>o <span class="blank _1"> </span>a <span class="blank _1"> </span>hem<span class="blank _1"> </span>orragias; </div><div class="t m0 xd h3 ye9 ff2 fs0 fc0 sc0 ls0 ws0">en <span class="blank _1"> </span>el <span class="blank _1"> </span>caso de <span class="blank _1"> </span>la <span class="blank _1"> </span>Warfarina se <span class="blank _1"> </span>desarrolla debido <span class="blank _1"> </span>a <span class="blank _1"> </span>la <span class="blank _2"> </span>intensidad <span class="blank _1"> </span>del efecto <span class="blank _1"> </span>anticoagula<span class="blank _0"></span>nte, <span class="blank _1"> </span>las </div><div class="t m0 xd h3 yea ff2 fs0 fc0 sc0 ls0 ws0">características <span class="blank _1b"> </span>del <span class="blank _1b"> </span>pa<span class="blank _1"> </span>ciente, <span class="blank _1b"> </span>el <span class="blank _1b"> </span>uso <span class="blank _1c"> </span>concomitante<span class="blank _1"> </span> <span class="blank _1b"> </span>de <span class="blank _1b"> </span>fármacos <span class="blank _1b"> </span>que <span class="blank _1c"> </span>interfieren <span class="blank _1b"> </span>con <span class="blank _1c"> </span>la </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div> <div id="pfa" class="pf w0 h0" data-page-no="a"><div class="pc pca w0 h0"><img fetchpriority="low" loading="lazy" class="bi x15 yc4 w7 hb" alt="" src="https://files.passeidireto.com/9fd98778-1c50-4964-98a9-badb0c5e2d2c/bga.png"><div class="t m0 x16 h8 yc5 ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 x17 hc yc6 ff4 fs1 fc0 sc0 ls0 ws0">Vicerrectoría de Investigaciones U<span class="blank _1"> </span>.D.C.A<span class="blank _0"></span> | Formato de Presentación ante proyecto de grado </div><div class="t m0 x19 hc yc7 ff4 fs1 fc0 sc0 ls0 ws0">Página <span class="ls12 wsf">10</span> </div><div class="t m0 xd h8 yc8 ff3 fs1 fc0 sc0 ls0 ws0"> </div><div class="t m0 xd h3 yc9 ff2 fs0 fc0 sc0 ls0 ws0">hemostasia <span class="blank _1d"> </span>y<span class="blank _0"></span> <span class="blank _1d"> </span>la <span class="blank _1d"> </span>duración<span class="blank _0"></span> <span class="blank _1d"> </span>de <span class="blank _1c"> </span>l<span class="blank _1"> </span>a <span class="blank _1e"> </span>terapia. <span class="blank _1d"> </span>L<span class="blank _b"></span>a <span class="blank _1d"> </span>intensida<span class="blank _1"> </span>d <span class="blank _1e"> </span>del <span class="blank _1e"> </span>efecto <span class="blank _1e"> </span>anticoagula<span class="blank _2"> </span>nte <span class="blank _1e"> </span>es </div><div class="t m0 xd h3 yeb ff2 fs0 fc0 sc0 ls0 ws0">probablemente e<span class="blank _0"></span>l fa<span class="blank _0"></span>ctor d<span class="blank _0"></span>e ri<span class="blank _0"></span>esg<span class="blank _0"></span>o más <span class="blank _0"></span>importante <span class="blank _0"></span>p<span class="blank _1"> </span>ara <span class="blank _0"></span>la <span class="blank _0"></span>hemorragia <span class="blank _0"></span>intracrane<span class="blank _0"></span>al <span class="blank _0"></span>c<span class="blank _1"> </span>uando <span class="blank _0"></span>los<span class="blank _0"></span> </div><div class="t m0 xd h3 yec ff2 fs0 fc0 sc0 ls0 ws0">valores del IN<span class="blank _0"></span>R se encuentra<span class="blank _1"> </span>n > 4,0 a 5,0<span class="blank _1"> </span> <span class="lsd wsd">(8)</span>. </div><div class="t m0 xd h3 yed ff2 fs0 fc0 sc0 ls0 ws0">L<span class="blank _0"></span>a frecuenc<span class="blank _1"> </span>ia de <span class="blank _0"></span>hemorragia <span class="blank _0"></span>grav<span class="blank _0"></span>e asociada a W<span class="blank _0"></span>arfarina se encuentra en<span class="blank _0"></span>tre <span class="blank _0"></span>10 a <span class="blank _0"></span>16%<span class="blank _2"> </span> según </div><div class="t m0 xd h3 yee ff2 fs0 fc0 sc0 ls0 ws0">cifras <span class="blank _0"></span>intern<span class="blank _0"></span>acionales. <span class="blank _b"></span>En los <span class="blank _a"></span>años <span class="blank _0"></span>2007 <span class="blank _b"></span>a <span class="blank _0"></span>2009 <span class="blank _b"></span>se <span class="blank _0"></span>realizó <span class="blank _b"></span>en <span class="blank _b"></span>E<span class="blank _1"> </span>EUU <span class="blank _b"></span>un <span class="blank _0"></span>estudio<span class="blank _0"></span> <span class="blank _0"></span>de <span class="blank _b"></span>los <span class="blank _b"></span>motivos </div><div class="t m0 xd h3 yef ff2 fs0 fc0 sc0 ls0 ws0">de hospitalización por eme<span class="blank _1"> </span>rgencia en paci<span class="blank _0"></span>entes mayores<span class="blank _0"></span> a 65 años.<span class="blank _1"> </span> Donde se determinó que </div><div class="t m0 xd h3 yf0 ff2 fs0 fc0 sc0 ls0 ws0">de <span class="blank _15"> </span>todas <span class="blank _2"> </span>l<span class="blank _1"> </span>as <span class="blank _2"> </span>emergencias <span class="blank _15"> </span>que <span class="blank _2"> </span>involu<span class="blank _1"> </span>cran <span class="blank _2"> </span>hem<span class="blank _1"> </span>orragias <span class="blank _2"> </span>intracraneales <span class="blank _18"> </span>y<span class="blank _0"></span> <span class="blank _15"> </span>gastrointestinales <span class="blank _15"> </span>se </div><div class="t m0 xd h3 yf1 ff2 fs0 fc0 sc0 ls0 ws0">atribuyen <span class="blank _0"></span>a medicación <span class="blank _0"></span>hematológ<span class="blank _0"></span>ica y<span class="blank _0"></span> de <span class="blank _0"></span>éstos <span class="blank _0"></span>el 63,3% <span class="blank _0"></span>se <span class="blank _0"></span>identificó a <span class="blank _0"></span>la W<span class="blank _0"></span>arfarina (s<span class="blank _0"></span>ola o<span class="blank _0"></span> </div><div class="t m0 xd h3 yf2 ff2 fs0 fc0 sc0 ls0 ws0">combinada) <span class="lsd wsd">(9)</span> </div><div class="t m0 xd h3 yf3 ff2 fs0 fc0 sc0 ls0 ws0">De <span class="blank _0"></span>ig<span class="blank _0"></span>ual <span class="blank _0"></span>importancia <span class="blank _b"></span>la Enoxap<span class="blank _0"></span>arina <span class="blank _0"></span>tiene<span class="blank _0"></span>n <span class="blank _0"></span>el <span class="blank _b"></span>potencial <span class="blank _0"></span>par<span class="blank _0"></span>a <span class="blank _0"></span>inducir <span class="blank _a"></span>l<span class="blank _1"> </span>a <span class="blank _0"></span>h<span class="blank _0"></span>emorragia<span class="blank _1"> </span>, <span class="blank _b"></span>m<span class="blank _1"> </span>ediante<span class="blank _0"></span> </div><div class="t m0 xd h3 yf4 ff2 fs0 fc0 sc0 ls0 ws0">la <span class="blank _15"> </span>i<span class="blank _1"> </span>nhibición <span class="blank _15"> </span>de <span class="blank _18"> </span>la <span class="blank _18"> </span>coag<span class="blank _0"></span>ulación <span class="blank _18"> </span>sanguínea, <span class="blank _2"> </span>al<span class="blank _1"> </span> <span class="blank _15"> </span>alt<span class="blank _1"> </span>erar <span class="blank _15"> </span>la <span class="blank _18"> </span>función <span class="blank _15"> </span>plaquetaria<span class="blank _1"> </span>,<span class="blank _2"> </span> <span class="blank _18"> </span>y<span class="blank _0"></span> <span class="blank _15"> </span>med<span class="blank _1"> </span>iante <span class="blank _18"> </span>el </div><div class="t m0 xd h3 yf5 ff2 fs0 fc0 sc0 ls0 ws0">aumento de la permeabilidad c<span class="blank _0"></span>apilar.<span class="blank _1"> </span> L<span class="blank _0"></span>a he<span class="blank _1"> </span>parina también puede producir <span class="blank _0"></span>trombocitopenia,<span class="blank _0"></span> </div><div class="t m0 xd h3 yf6 ff2 fs0 fc0 sc0 ls0 ws0">pero esto rara vez<span class="blank _0"></span> es una causa im<span class="blank _1"> </span>portante de sang<span class="blank _0"></span>rado<span class="blank _1"> </span> <span class="lsd wsd">(8)</span>. </div><div class="t m0 xd h3 yf7 ff2 fs0 fc0 sc0 ls0 ws0">El <span class="blank _1"> </span>uso <span class="blank _1"> </span>c<span class="blank _1"> </span>oncomitante <span class="blank _1"> </span>de <span class="blank _1"> </span>l<span class="blank _1"> </span>os anticoagulantes, <span class="blank _1"> </span>incrementa<span class="blank _1"> </span> la<span class="blank _1"> </span> <span class="blank _2"> </span>incidencia <span class="blank _1"> </span>de <span class="blank _2"> </span>hemorrag<span class="blank _0"></span>ia <span class="blank _1"> </span>de<span class="blank _1"> </span>bido<span class="blank _0"></span> </div><div class="t m0 xd h3 y9a ff2 fs0 fc0 sc0 lsc ws0">al <span class="blank _1"> </span><span class="ls0">desarrollo <span class="blank _1"> </span>de<span class="blank _1"> </span> <span class="blank _1"> </span>posibles <span class="blank _2"> </span>interacciones <span class="blank _1"> </span>medicamentosas, <span class="blank _1"> </span>a<span class="blank _1"> </span>sí <span class="blank _1"> </span>como <span class="blank _1"> </span>la <span class="blank _2"> </span>dificultad <span class="blank _1"> </span>para <span class="blank _1"> </span>obtener </span></div><div class="t m0 xd h3 y7b ff2 fs0 fc0 sc0 ls0 ws0">valores terapéuticos de ant<span class="blank _1"> </span>icoagulación (2). Los casos gra<span class="blank _1"> </span>ves s<span class="blank _0"></span>e generan cua<span class="blank _1"> </span>ndo comprende </div><div class="t m0 xd h3 yf8 ff2 fs0 fc0 sc0 ls0 ws0">daños <span class="blank"> </span>irreversibles <span class="blank"> </span>en <span class="blank"> </span>estructuras <span class="blank"> </span>v<span class="blank _0"></span>itales <span class="blank"> </span>como <span class="blank"> </span>medula <span class="blank"> </span>espinal, <span class="blank"> </span>estructura <span class="blank"> </span>in<span class="blank _0"></span>tracraneal, </div><div class="t m0 xd h3 yf9 ff2 fs0 fc0 sc0 ls0 ws0">membrana <span class="blank _2"> </span>pericárdica, <span class="blank _1"> </span> <span class="blank _2"> </span>e<span class="blank _1"> </span>ntre <span class="blank _1"> </span>otros; <span class="blank _2"> </span>además <span class="blank _1"> </span>de <span class="blank _2"> </span>posibles <span class="blank _2"> </span>hemorragias <span class="blank _1"> </span>inte<span class="blank _1"> </span>rnas <span class="blank _1"> </span>o <span class="blank _2"> </span>hematomas </div><div class="t m0 xd h3 y5d ff2 fs0 fc0 sc0 ls0 ws0">intracerebrales <span class="lsd wsd">(5)</span> <span class="lsd wsd">(10)</span><span class="ls10"> <span class="lsd wsd">(11)</span></span>. </div><div class="t m0 xd h3 yfa ff2 fs0 fc0 sc0 ls0 ws0"> A<span class="blank _0"></span> pesar, <span class="blank _0"></span> <span class="blank _0"></span>de los <span class="blank _0"></span>posibles factores <span class="blank _b"></span>de<span class="blank _1"> </span> riesg<span class="blank _0"></span>o, <span class="lse wse">la</span> Enox<span class="blank _0"></span>aparina <span class="blank _0"></span>es frecuent<span class="blank _0"></span>emente usada<span class="blank _0"></span> durant<span class="blank _0"></span>e </div><div class="t m0 xd h3 yfb ff2 fs0 fc0 sc0 ls0 ws0">el <span class="blank _16"> </span>inicio <span class="blank _19"> </span>de <span class="blank _19"> </span>la <span class="blank _16"> </span>terapia <span class="blank _19"> </span>con <span class="blank _16"> </span>Warfarina<span class="blank _1"> </span>, <span class="blank _19"> </span>con <span class="blank _19"> </span>el <span class="blank _16"> </span>fin <span class="blank _19"> </span>de <span class="blank _16"> </span>asegurar <span class="blank _19"> </span>la <span class="blank _19"> </span>anticoagulación <span class="blank _19"> </span>y <span class="blank _19"> </span>pa<span class="blank _1"> </span>ra <span class="blank _19"> </span>la </div><div class="t m0 xd h3 yfc ff2 fs0 fc0 sc0 ls0 ws0">protección <span class="blank _1b"> </span>frente <span class="blank _1b"> </span>a <span class="blank _1b"> </span>la <span class="blank _1b"> </span>hipercoagulabilidad <span class="blank _1b"> </span>transitoria <span class="blank _1b"> </span>d<span class="blank _1"> </span>urante <span class="blank _1b"> </span>los <span class="blank _1b"> </span>primeros <span class="blank _1b"> </span>5 <span class="blank _1b"> </span>días <span class="blank _1b"> </span>de </div><div class="t m0 xd h3 yfd ff2 fs0 fc0 sc0 ls0 ws0">tratamiento y<span class="blank _b"></span>a<span class="blank _1"> </span> que <span class="blank _0"></span>los <span class="blank _0"></span>efectos <span class="blank _0"></span>de <span class="blank _0"></span>la <span class="blank _0"></span>Warfarina tienen<span class="blank _0"></span> un <span class="blank _0"></span>pi<span class="blank _0"></span>co d<span class="blank _0"></span>e a<span class="blank _0"></span>cción <span class="blank _0"></span>a <span class="blank _0"></span>las 72 <span class="blank _b"></span>horas<span class="blank _1"> </span>, <span class="blank _b"></span>pue<span class="blank _1"> </span>sto </div><div class="t m0 xd h3 yfe ff2 fs0 fc0 sc0 ls0 ws0">que <span class="blank _1"> </span>aún <span class="blank _2"> </span>persisten <span class="blank _1"> </span>factores <span class="blank _1"> </span>de<span class="blank _1"> </span> c<span class="blank _1"> </span>oagulación<span class="blank _0"></span> <span class="blank _1"> </span>presentes <span class="blank _1"> </span>e<span class="blank _1"> </span>n el<span class="blank _1"> </span> <span class="blank _1"> </span>plasma<span class="blank _1"> </span>. <span class="blank _2"> </span> <span class="blank _1"> </span>Por <span class="blank _1"> </span>otra <span class="blank _1"> </span>parte, <span class="blank _1"> </span> <span class="blank _2"> </span>al <span class="blank _1"> </span>iniciar </div><div class="t m0 xd h3 yff ff2 fs0 fc0 sc0 ls0 ws0">la administración <span class="blank _0"></span>de <span class="blank _0"></span>la W<span class="blank _0"></span>arfarina <span class="blank _0"></span>e<span class="blank _0"></span>l niv<span class="blank _0"></span>el <span class="blank _0"></span>de proteína <span class="blank _0"></span>C <span class="blank _0"></span>disminuy<span class="blank _0"></span>e más <span class="blank _0"></span>rápidamente <span class="blank _b"></span>que<span class="blank _1"> </span> los<span class="blank _0"></span> </div><div class="t m0 xd h3 y48 ff2 fs0 fc0 sc0 ls0 ws0">niveles <span class="blank _18"> </span>de <span class="blank _18"> </span>los <span class="blank _18"> </span>fact<span class="blank _1"> </span>ores <span class="blank _18"> </span>II<span class="blank _0"></span>, <span class="blank _18"> </span>IX, <span class="blank _19"> </span>y <span class="blank _18"> </span>X, <span class="blank _18"> </span> <span class="blank _19"> </span>generándose <span class="blank _18"> </span>un <span class="blank _18"> </span>estado <span class="blank _18"> </span>proc<span class="blank _1"> </span>oagulante<span class="blank _1"> </span>, <span class="blank _18"> </span>re<span class="blank _1"> </span>quiri<span class="blank _0"></span>endo <span class="blank _18"> </span>un </div><div class="t m0 xd h3 y100 ff2 fs0 fc0 sc0 ls0 ws0">tratamiento concomitante con H<span class="blank _0"></span>BPM <span class="lsd wsd">(6)</span><span class="ls11"> <span class="lsd wsd">(12)</span></span> <span class="lsd wsd">(13)</span>. </div><div class="t m0 xd h3 y101 ff2 fs0 fc0 sc0 ls0 ws0">En <span class="blank _1d"> </span>pacientes <span class="blank _1d"> </span>t<span class="blank _1"> </span>ratados <span class="blank _1e"> </span>con <span class="blank _1d"> </span>a<span class="blank _1"> </span>nticoag<span class="blank _0"></span>ulantes <span class="blank _1d"> </span>y<span class="blank _0"></span> <span class="blank _1d"> </span>que<span class="blank _1"> </span> <span class="blank _1f"> </span>serán <span class="blank _1d"> </span>someti<span class="blank _1"> </span>dos <span class="blank _1e"> </span>a<span class="blank _1"> </span> <span class="blank _1d"> </span>procedimientos<span class="blank _0"></span> </div><div class="t m0 xd h3 y16 ff2 fs0 fc0 sc0 ls0 ws0">quirúrgicos; al suspender el a<span class="blank _1"> </span>ntico<span class="blank _0"></span>agulante se corre el riesgo de un fenómeno embólico o el </div><div class="t m0 xd h3 y4b ff2 fs0 fc0 sc0 ls0 ws0">riesgo de <span class="blank _1"> </span>sangrado e<span class="blank _1"> </span>n c<span class="blank _1"> </span>aso de <span class="blank _1"> </span>conti<span class="blank _1"> </span>nuar e<span class="blank _1"> </span>l t<span class="blank _1"> </span>ratamiento. De <span class="blank _1"> </span>hecho, <span class="blank _1"> </span>los <span class="blank _1"> </span>accide<span class="blank _1"> </span>ntes vasculares<span class="blank _0"></span> </div><div class="t m0 xd h3 y102 ff2 fs0 fc0 sc0 ls0 ws0">embólicos se asocian con <span class="blank _0"></span>muerte o d<span class="blank _0"></span>iscapacidad neurológic<span class="blank _0"></span>a severa en<span class="blank _1"> </span> un 70% de los casos<span class="blank _0"></span>, </div><div class="t m0 xd h3 y103 ff2 fs0 fc0 sc0 ls0 ws0">mientras que <span class="blank _0"></span>los fenó<span class="blank _0"></span>menos <span class="blank _0"></span>tromboembolí<span class="lse">ti</span>cos v<span class="blank _b"></span>e<span class="blank _1"> </span>nosos <span class="blank _0"></span>se <span class="blank _0"></span>asocia con un<span class="blank _0"></span>a <span class="blank _0"></span>mortalidad<span class="blank _0"></span> de <span class="blank _0"></span>4%<span class="blank _0"></span> </div><div class="t m0 xd h3 y34 ff2 fs0 fc0 sc0 ls0 ws0">a <span class="blank _1"> </span>9%, <span class="blank _1"> </span>razón <span class="blank _1"> </span>por <span class="blank _1"> </span>la <span class="blank _1"> </span>cual, <span class="blank _1"> </span> <span class="blank _1"> </span> es<span class="blank _1"> </span> <span class="blank _1"> </span> nec<span class="blank _1"> </span>esario, <span class="blank _1"> </span> <span class="blank _1"> </span>establecer <span class="blank _1"> </span>la <span class="blank _1"> </span> <span class="blank _1"> </span>terapia <span class="blank _1"> </span>puente e<span class="blank _1"> </span>n<span class="blank _2"> </span> <span class="blank _1"> </span>la <span class="blank _1"> </span>que <span class="blank _1"> </span>se suspende </div><div class="t m0 xd h3 y104 ff2 fs0 fc0 sc0 ls0 ws0">el <span class="blank _f"> </span>consumo <span class="blank _16"> </span>de<span class="blank _1"> </span> <span class="blank _16"> </span>la <span class="blank _f"> </span>Warfarina <span class="blank _f"> </span>y<span class="blank _0"></span> <span class="blank _16"> </span>se <span class="blank _f"> </span>i<span class="blank _1"> </span>nicia <span class="blank _16"> </span>el <span class="blank _f"> </span>uso <span class="blank _f"> </span>de <span class="blank _17"> </span>Enoxaparina, <span class="blank _f"> </span>con <span class="blank _16"> </span>la<span class="blank _1"> </span> <span class="blank _f"> </span>ventaja <span class="blank _16"> </span>de <span class="blank _f"> </span>poder<span class="blank _0"></span> </div><div class="t m0 xd h3 y105 ff2 fs0 fc0 sc0 ls0 ws0">suspenderla horas antes del procedimiento. <span class="lsd wsd">(4)</span> <span class="lsd wsd">(14)</span>. </div></div><div class="pi" data-data="{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}"></div></div>
Compartir